What is a drug product pipeline?
The pipeline refers to potential drugs or vaccines in development but not yet approved for a given company. It may consist of new agents that are not on market or agents already on market but being studied for new indications.
A company’s drug pipeline is often summarized by organizing investigational agents by where they are in the drug development cycle – specifically whether they are in discovery, pre-clinical testing, phase I, phase II, or phase III.
Having a strong pipeline is often key to sustainable growth for pharmaceutical companies. They can often be found on company websites and in communications to investor relations. Payers often ask pharmaceutical companies (specifically outcomes liaison teams) to present on their pipeline in order to better understand potential future costs and market dynamics.